StockData
STAAR Surgical Co logo

STAAR Surgical Co (STAA) stock

STAANasdaqOphthalmic GoodsFiscal year ends January 2
Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 12, 2026Score 10/3060% above fair value
$24.54−0.70 (-2.77%)

Close on Oct 30, 2026Market cap $1.23BP/E 350.6Yield –

Earnings

STAAR Surgical's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 4, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$93.50M
+111.1% on a year earlier
Adjusted EBITDA per diluted share, Q2 FY2026
$0.39
-$0.30 a year earlier
Latest guidance
Raised
May 7, 2025 · 1 item

Quarterly results

Revenue and earnings per share from each of STAAR Surgical's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2026ended Sep 26, 2026Nov 4, 2026Expected–––––
Q2 FY2026ended Jul 3, 2026Aug 12, 2026after the close$93.50M+111.1%$0.16$0.39Release
Q1 FY2026ended Apr 3, 2026May 13, 2026after the close$93.50M+119.5%$0.10$0.48Release
Q4 FY2025ended Jan 2, 2026Mar 3, 2026after the close$57.80M+18.0%-$0.37–Release
Q3 FY2025ended Sep 26, 2025Nov 5, 2025after the close$94.70M+6.9%$0.18$0.68Release
Q2 FY2025ended Jun 27, 2025Aug 6, 2025after the close$44.30M-55.3%-$0.34-$0.30Release
Q1 FY2025ended Mar 28, 2025May 7, 2025after the close$42.60M-45.0%-$1.10-$0.53Release
Q4 FY2024ended Dec 27, 2024Feb 11, 2025after the close$49.00M-35.8%-$0.69–Release
Q3 FY2024ended Sep 27, 2024Oct 30, 2024after the close$88.60M+10.3%$0.20$0.33Release
Q2 FY2024ended Jun 28, 2024Aug 7, 2024after the close$99.00M+7.3%$0.15$0.45Release
Q1 FY2024ended Mar 29, 2024May 7, 2024after the close$77.40M+5.3%-$0.07$0.11Release
Q4 FY2023ended Dec 29, 2023Feb 26, 2024after the close$76.30M+19.2%$0.16–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period STAAR Surgical guided for has been reported

Guidance history

Every forecast STAAR Surgical put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
May 7, 2025annualized SG&A run rateFY2025$225.00MRaised
Feb 11, 2025Adjusted EBITDA lossFY2025-$30.00MNew
Feb 11, 2025Adjusted EBITDA gain rangeFY2025$5.00M – $22.50MRaised
Feb 11, 2025Adjusted EBITDA loss rangeFY2025-$50.00M – -$15.00MLowered
Feb 11, 2025Adjusted EBITDA per diluted share loss rangeFY2025-$1.00 – -$0.30New
Feb 11, 2025cash, cash equivalents and investments available for saleFY2025$150.00M – $175.00MNew
Feb 11, 2025ICL sales Ex. China growthFY2025+9% – +15%New
Feb 11, 2025ICL sales Ex. ChinaFY2025$165.00M – $175.00MNew
Feb 11, 2025China ICL salesFY2025$75.00M – $125.00MLowered
Oct 30, 2024Adjusted EBITDAFY2024$42.00MReaffirmed
Oct 30, 2024EVO ICL sales growth in the AmericasFY2024+17%New
Oct 30, 2024EVO ICL sales growth in the U.S.FY2024+20%Raised
Oct 30, 2024EMEA sales growthFY2024+10%Lowered
Oct 30, 2024APAC sales growthFY2024+4%Lowered
Oct 30, 2024growth in ChinaFY2024+2%Lowered
Oct 30, 2024Adjusted EBITDA per diluted shareFY2024$0.80Raised
Oct 30, 2024Net salesFY2024$340.00M – $345.00MReaffirmed
Aug 7, 2024Adjusted EBITDAFY2024$42.00MRaised
Aug 7, 2024Adjusted EBITDA per diluted shareFY2024$0.80Raised
Aug 7, 2024Net salesFY2024$340.00M – $345.00MRaised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases STAAR Surgical filed with the SEC as exhibits to Form 8-K or 6-K

  1. STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer
    Update
  2. STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer
    Update
  3. STAAR Surgical Reports Second Quarter 2026 Results
    Results
  4. STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer
    Update
  5. STAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter
    Results
  6. STAAR Surgical Announces Preliminary Net Sales for First Quarter 2026
    Update
  7. STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results
    Results
  8. STAAR Surgical Issues Shareholder Letter
    Results
  9. STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs
    Update
  10. STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement
    News
  11. STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders
    News
  12. STAAR Surgical Announces Expiration of Go-Shop Period
    News
  13. STAAR Surgical Announces Amendments to Alcon Merger Agreement
    News
  14. STAAR Surgical Reports Third Quarter 2025 Results
    Results
  15. STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon
    News